Inovio unit gets approval in South Korea to test avian flu vaccine

03/2/2010 | American City Business Journals

Inovio Biomedical said regulators in South Korea granted its affiliate, VGX International, approval to begin a first-stage trial of an experimental DNA vaccine against H5N1 flu. Inovio said it plans to start testing the vaccine in the U.S. later this year as it works on a DNA-based universal flu vaccine.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA